Q2 FY2024 · ended Jun 30, 2024 · Revenue $17,479, +76.0% YoY · Filed Aug 19, 2024
Axim Biotechnologies, Inc. (AXIM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2024, the quarter ended Jun 30, 2024, it reported revenue of $17,479 and a net loss of $2.3 million. As of Jun 30, 2024 it held $6,044 in cash and investments and $6.0 million in total debt.
Revenue
$17,479
+76.0% vs year-ago quarter
Net income
$-2.27M
+39.0% vs year-ago quarter
Operating cash flow
$-261,542
+59.4% vs year-ago quarter
Free cash flow
$-255,345
-1405.7% vs prior quarter
EPS
$-0.01
+50.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
301.96M
+29.2% vs year-ago quarter
Net cash
$-5.96M
Q2 FY2024
Operating margin
-2490.3%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AXIM (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1514946
- Former names
- AXIM INTERNATIONAL INC. (until Aug 13, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2024 Jun 30, 2024 |
Q1 FY2024 Mar 31, 2024 |
Q4 FY2023 Dec 31, 2023 |
Q3 FY2023 Sep 30, 2023 |
Q2 FY2023 Jun 30, 2023 |
|---|---|---|---|---|---|
| Revenue | $17,479 | $52,979 | $12,859 | $9,581 | $9,929 |
| Operating income | -$569,441 | -$401,563 | -$753,940 | -$588,535 | -$697,729 |
| Net income | -$2.3M | -$292,299 | -$1.9M | $328,470 | -$3.7M |
| Diluted EPS | -$0.01 | -$0.00 | — | $0.00 | -$0.02 |
| Operating cash flow | -$261,542 | -$252,506 | $19,556 | -$264,503 | -$643,594 |
| Free cash flow | — | -$255,345 | $19,556 | -$270,503 | — |
| Total assets | $3.7M | $3.9M | $4.1M | $4.0M | $4.2M |
| Total liabilities | $13.3M | $11.4M | $11.8M | $10.0M | $14.0M |
| Stockholders' equity | -$9.5M | -$7.4M | -$7.7M | -$6.0M | -$9.8M |
| Cash and investments | $6,044 | $96,711 | $156,457 | $23,220 | $97,498 |
| Total debt | $6.0M | $118,031 | $231,873 | $254,082 | $275,969 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Change in control, Officer or director change
|
Oct 15, 2024 | Oct 9, 2024 |
| 10-Q | Quarterly report | Aug 19, 2024 | Jun 30, 2024 |
| 10-Q/A | Amended quarterly report | May 22, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | May 20, 2024 | Mar 31, 2024 |
| 10-K | Annual report | Apr 16, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 21, 2024 | Mar 15, 2024 |
All 306 Axim Biotechnologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.